BR112013002651A2 - forma sólida do sal de cloridrato de 4-[2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oxi]etil]morfolina, processo para o preparo da mesma, uso mesma e composição farmacêutica compreendendo a mesma - Google Patents
forma sólida do sal de cloridrato de 4-[2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oxi]etil]morfolina, processo para o preparo da mesma, uso mesma e composição farmacêutica compreendendo a mesmaInfo
- Publication number
- BR112013002651A2 BR112013002651A2 BR112013002651A BR112013002651A BR112013002651A2 BR 112013002651 A2 BR112013002651 A2 BR 112013002651A2 BR 112013002651 A BR112013002651 A BR 112013002651A BR 112013002651 A BR112013002651 A BR 112013002651A BR 112013002651 A2 BR112013002651 A2 BR 112013002651A2
- Authority
- BR
- Brazil
- Prior art keywords
- same
- naphthalenyl
- pyrazol
- oxy
- ethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10382225A EP2426111A1 (en) | 2010-08-09 | 2010-08-09 | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms |
PCT/EP2011/063583 WO2012019984A1 (en) | 2010-08-09 | 2011-08-08 | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013002651A2 true BR112013002651A2 (pt) | 2016-05-31 |
Family
ID=43244877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013002651A BR112013002651A2 (pt) | 2010-08-09 | 2011-08-08 | forma sólida do sal de cloridrato de 4-[2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oxi]etil]morfolina, processo para o preparo da mesma, uso mesma e composição farmacêutica compreendendo a mesma |
Country Status (19)
Country | Link |
---|---|
US (1) | US9428462B2 (pt) |
EP (2) | EP2426111A1 (pt) |
JP (1) | JP5899214B2 (pt) |
KR (1) | KR20130095751A (pt) |
CN (1) | CN103052626B (pt) |
AR (1) | AR082608A1 (pt) |
AU (1) | AU2011288550A1 (pt) |
BR (1) | BR112013002651A2 (pt) |
CA (1) | CA2807855C (pt) |
CO (1) | CO6670586A2 (pt) |
ES (1) | ES2543429T3 (pt) |
HK (1) | HK1186468A1 (pt) |
MA (1) | MA34512B1 (pt) |
MX (1) | MX341711B (pt) |
PT (1) | PT2603495E (pt) |
RU (1) | RU2013110313A (pt) |
SG (1) | SG187745A1 (pt) |
TW (1) | TW201219387A (pt) |
WO (1) | WO2012019984A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2116539A1 (en) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
EP2353591A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
EP2353598A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
EP2388005A1 (en) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
EP2415471A1 (en) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
EP2524694A1 (en) | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
EP2792352A1 (en) | 2013-04-16 | 2014-10-22 | Laboratorios Del. Dr. Esteve, S.A. | Alpha-2 adrenoreceptor and sigma receptor ligand combinations |
MX2016007286A (es) | 2013-12-17 | 2016-08-04 | Esteve Labor Dr | Combinaciones de gabapentinoides y ligandos de receptores sigma. |
AU2014364647A1 (en) | 2013-12-17 | 2016-06-23 | Laboratorios Del Dr. Esteve, S.A. | Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Sigma receptor ligands combinations |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04364129A (ja) * | 1990-10-26 | 1992-12-16 | Asahi Chem Ind Co Ltd | 6−置換アルコキシキノキサリン誘導体含有医薬組成物およびその製造法 |
SE508669C2 (sv) | 1996-04-26 | 1998-10-26 | Astra Ab | Nytt förfarande |
EP1634872A1 (en) * | 2004-08-27 | 2006-03-15 | Laboratorios Del Dr. Esteve, S.A. | Pyrazole derivatives as sigma receptor inhibitors |
US7696199B2 (en) * | 2004-08-27 | 2010-04-13 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
RU2417987C2 (ru) * | 2004-08-27 | 2011-05-10 | Лабораторьос Дель Др.Эстеве, С.А. | Ингибиторы сигма-рецептора |
JPWO2009038112A1 (ja) | 2007-09-21 | 2011-01-06 | 塩野義製薬株式会社 | Npyy5受容体拮抗剤を含有する固形製剤 |
EP2116539A1 (en) * | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
EP2113501A1 (en) * | 2008-04-25 | 2009-11-04 | Laboratorios Del. Dr. Esteve, S.A. | 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors |
EP2292236A1 (en) * | 2009-08-14 | 2011-03-09 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention or treatment of pain induced by chemotherapy |
EP2361904A1 (en) | 2010-02-04 | 2011-08-31 | Laboratorios Del. Dr. Esteve, S.A. | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride and crystalline forms thereof |
EP2335688A1 (en) * | 2009-11-25 | 2011-06-22 | Laboratorios Del. Dr. Esteve, S.A. | Pharmaceutical compositions comprising sigma receptor ligands |
DK2503993T3 (en) * | 2009-11-25 | 2016-08-22 | Esteve Labor Dr | Hydrochloridsalt af 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]-morpholin |
SG182628A1 (en) * | 2010-02-04 | 2012-08-30 | Esteve Labor Dr | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates |
EP2353598A1 (en) * | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
EP2426112A1 (en) | 2010-08-09 | 2012-03-07 | Laboratorios Del. Dr. Esteve, S.A. | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates |
EP2388005A1 (en) * | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
EP2415471A1 (en) * | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
EP2460519A1 (en) * | 2010-12-03 | 2012-06-06 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in bone cancer pain |
-
2010
- 2010-08-09 EP EP10382225A patent/EP2426111A1/en not_active Withdrawn
-
2011
- 2011-08-08 BR BR112013002651A patent/BR112013002651A2/pt not_active Application Discontinuation
- 2011-08-08 WO PCT/EP2011/063583 patent/WO2012019984A1/en active Application Filing
- 2011-08-08 MA MA35713A patent/MA34512B1/fr unknown
- 2011-08-08 CA CA2807855A patent/CA2807855C/en not_active Expired - Fee Related
- 2011-08-08 RU RU2013110313/04A patent/RU2013110313A/ru not_active Application Discontinuation
- 2011-08-08 US US13/816,194 patent/US9428462B2/en not_active Expired - Fee Related
- 2011-08-08 KR KR1020137006090A patent/KR20130095751A/ko not_active Application Discontinuation
- 2011-08-08 TW TW100128160A patent/TW201219387A/zh unknown
- 2011-08-08 AU AU2011288550A patent/AU2011288550A1/en not_active Abandoned
- 2011-08-08 MX MX2013001559A patent/MX341711B/es active IP Right Grant
- 2011-08-08 CN CN201180038821.9A patent/CN103052626B/zh not_active Expired - Fee Related
- 2011-08-08 SG SG2013009220A patent/SG187745A1/en unknown
- 2011-08-08 JP JP2013523580A patent/JP5899214B2/ja not_active Expired - Fee Related
- 2011-08-08 PT PT117406751T patent/PT2603495E/pt unknown
- 2011-08-08 EP EP20110740675 patent/EP2603495B1/en active Active
- 2011-08-08 ES ES11740675.1T patent/ES2543429T3/es active Active
- 2011-08-09 AR ARP110102890A patent/AR082608A1/es unknown
-
2013
- 2013-02-08 CO CO13026634A patent/CO6670586A2/es not_active Application Discontinuation
- 2013-12-16 HK HK13113963.1A patent/HK1186468A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP2603495A1 (en) | 2013-06-19 |
MA34512B1 (fr) | 2013-09-02 |
HK1186468A1 (en) | 2014-03-14 |
US9428462B2 (en) | 2016-08-30 |
KR20130095751A (ko) | 2013-08-28 |
US20130150575A1 (en) | 2013-06-13 |
WO2012019984A1 (en) | 2012-02-16 |
MX341711B (es) | 2016-08-31 |
JP2013533298A (ja) | 2013-08-22 |
ES2543429T3 (es) | 2015-08-19 |
EP2426111A1 (en) | 2012-03-07 |
AU2011288550A1 (en) | 2013-02-21 |
AR082608A1 (es) | 2012-12-19 |
CA2807855C (en) | 2018-10-23 |
CN103052626A (zh) | 2013-04-17 |
SG187745A1 (en) | 2013-03-28 |
JP5899214B2 (ja) | 2016-04-06 |
TW201219387A (en) | 2012-05-16 |
CN103052626B (zh) | 2017-06-06 |
CO6670586A2 (es) | 2013-05-15 |
MX2013001559A (es) | 2013-03-07 |
RU2013110313A (ru) | 2014-09-20 |
CA2807855A1 (en) | 2012-02-16 |
PT2603495E (pt) | 2015-08-28 |
EP2603495B1 (en) | 2015-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013002651A2 (pt) | forma sólida do sal de cloridrato de 4-[2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oxi]etil]morfolina, processo para o preparo da mesma, uso mesma e composição farmacêutica compreendendo a mesma | |
BRPI0818193A2 (pt) | composto, sal farmacêuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto | |
BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
BRPI0817200A2 (pt) | composições oftálmicas sólida e uso de compostos para fabricação de medicamento | |
BR112014003802A2 (pt) | composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento | |
BRPI1006162A2 (pt) | "composto,processo para preparar um composto,formulação farmacêutica,e uso de um composto". | |
BRPI1013763A2 (pt) | Composto ou sal do mesmo, prodroga, composição farmacêutica, agente diminuidor da proteína de ligação de retinol 4, agente para a profilaxia ou tratamento de diabetes, e, uso de um composto | |
BR112014016287A2 (pt) | composto, composição farmacêutica, método para aumentar a inclusão de exon 7 de smn2, método para aumentar a quantidade de proteína, método para o tratamento de sma | |
BR112013023174A2 (pt) | "compostos derivados de triterpenoide de c4-monometila, composição farmacêutica compreendendo os referidos compostos e uso dos mesmos" | |
BR112014011671A2 (pt) | composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto | |
BRPI0906475A2 (pt) | Compostos, processso para a preparação de um composto, composição farmacêutica e uso de um composto | |
BRPI1012993A2 (pt) | "uso de um anticorpo anti-tau ps422 para o tratamento de doenças do cérebro" | |
BRPI0917705A2 (pt) | composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto | |
BRPI0607423A2 (pt) | forma microcristalina de um composto, processo para a preparação da mesma, uso de uma forma microcristalina, composição farmacêutica e processo para a preparação da mesma, e, produto | |
BRPI0911685A2 (pt) | composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit | |
BRPI0817597A2 (pt) | Compostos de diarila de oxadiazol, processo para sua preparação, composições farmacêuticas e kit compreendendo os mesmos, bem como seus usos | |
BRPI0907977A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
CL2008000403A1 (es) | Compuestos derivados de pentafluorotiobenzamido-acetonitrilo; composicion farmaceutica; y uso para tratar una infestacion por parasitos. | |
BR112012026570A2 (pt) | composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado | |
BRPI0809661A2 (pt) | Composição farmacêutica estabilizada contendo pregabalina | |
PL2503993T3 (pl) | Chlorowodorek 4-[2-[[5-metylo-1-(2-naftalenylo)-1H-pirazol-3-ilo]oksy]etylo]morfoliny | |
CO6801754A2 (es) | Una composición farmacéutica para tratar una enfermedad en la cavidad oral que comprende rebamipida | |
BRPI0907974A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
BRPI0913212A2 (pt) | composto de carbinol, remédio, regulador de lxr, composição farmacêutica, método para prevenir e/ou tratar doença, e, uso do derivado de carbinol ou sal do mesmo, ou seu solvato | |
BRPI1012979A2 (pt) | composição para cuidado oral, método para preparar a mesma, e, uso de um composto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |